Constitutively active GSK3 beta as a means to bolster dendritic cell functionality in the face of tumor-mediated immune suppression by Gonzalez, Marta Lopez et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: https://www.tandfonline.com/loi/koni20
Constitutively active GSK3β as a means to bolster
dendritic cell functionality in the face of tumour-
mediated immune suppression
Marta López González, Dinja Oosterhoff, Jelle J. Lindenberg, Ioanna
Milenova, Sinead M. Lougheed, Tania Martiáñez, Henk Dekker, Dafne
Carolina Alves Quixabeira, Basav Hangalapura, Jos Joore, Sander R. Piersma,
Victor Cervera-Carrascon, Joao Manuel Santos, Rik J. Scheper, Henk M.W.
Verheul, Connie R. Jiménez, Rieneke Van De Ven, Akseli Hemminki, Victor W.
Van Beusechem & Tanja D. De Gruijl
To cite this article: Marta López González, Dinja Oosterhoff, Jelle J. Lindenberg, Ioanna Milenova,
Sinead M. Lougheed, Tania Martiáñez, Henk Dekker, Dafne Carolina Alves Quixabeira, Basav
Hangalapura, Jos Joore, Sander R. Piersma, Victor Cervera-Carrascon, Joao Manuel Santos, Rik
J. Scheper, Henk M.W. Verheul, Connie R. Jiménez, Rieneke Van De Ven, Akseli Hemminki, Victor
W. Van Beusechem & Tanja D. De Gruijl (2019) Constitutively active GSK3β as a means to bolster
dendritic cell functionality in the face of tumour-mediated immune suppression, OncoImmunology,
8:10, e1631119, DOI: 10.1080/2162402X.2019.1631119
To link to this article:  https://doi.org/10.1080/2162402X.2019.1631119
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 19 Jul 2019. Submit your article to this journal 
Article views: 1020 View related articles 
View Crossmark data
ORIGINAL RESEARCH
Constitutively active GSK3β as a means to bolster dendritic cell functionality in the
face of tumor-mediated immune suppression
Marta López Gonzáleza*, Dinja Oosterhoffa*, Jelle J. Lindenberg*a, Ioanna Milenovaa, Sinead M. Lougheeda,
Tania Martiáñeza, Henk Dekkera, Dafne Carolina Alves Quixabeirab,c, Basav Hangalapuraa, Jos Joored,
Sander R. Piersmaa, Victor Cervera-Carrascon b,c, Joao Manuel Santosb,c, Rik J. Schepere, Henk M.W. Verheula,
Connie R. Jiméneza, Rieneke Van De Vena, Akseli Hemminkib,c,f, Victor W. Van Beusechema, and Tanja D. De Gruijla
aDepartment of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV
Amsterdam, The Netherlands; bCancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of
Helsinki, Helsinki, Finland; cTILT Biotherapeutics Ltd, Helsinki, Finland; dPepScope B.V., VB Utrecht, Netherlands; eDepartment of Pathology,
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, HV Amsterdam, The Netherlands; fDepartment
Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
ABSTRACT
In patients with cancer, the functionality of Dendritic Cells (DC) is hampered by high levels of tumor-
derived suppressive cytokines, which interfere with DC development and maturation. Poor DC devel-
opment can limit the efficacy of immune checkpoint blockade and in vivo vaccination approaches.
Interference in intracellular signaling cascades downstream from the receptors of major tumor-
associated suppressive cytokines like IL-10 and IL-6, might improve DC development and activation,
and thus enhance immunotherapy efficacy. We performed exploratory functional screens on arrays
consisting of >1000 human kinase peptide substrates to identify pathways involved in DC development
and its inhibition by IL-10 or IL-6. The resulting alterations in phosphorylation of the kinome substrate
profile pointed to glycogen-synthase kinase-3β (GSK3β) as a pivotal kinase in both DC development and
suppression. GSK3β inhibition blocked human DC differentiation in vitro, which was accompanied by
decreased levels of IL-12p70 secretion, and a reduced capacity for T cell priming. More importantly,
adenoviral transduction of monocytes with a constitutively active form of GSK3β induced resistance to
the suppressive effects of IL-10 and melanoma-derived supernatants alike, resulting in improved DC
development, accompanied by up-regulation of co-stimulatory markers, an increase in CD83 expression
levels in mature DC, and diminished release of IL-10. Moreover, adenovirus-mediated intratumoral
manipulation of this pathway in an in vivo melanoma model resulted in DC activation and recruitment,
and in improved immune surveillance and tumor control. We propose the induction of constitutive
GSK3β activity as a novel therapeutic means to bolster DC functionality in the tumor microenvironment.
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Introduction
Dendritic cells (DC) are the most powerful antigen-presenting cells
and play a crucial role in the induction and maintenance of immune
responses.1 A growing number of pre-clinical reports show the feasi-
bility of targeting and activating DC in vivo as respective means of
anti-tumor vaccination and immune potentiation.2–4 In addition,
more recent studies have demonstrated the importance of the pre-
sence of activatedDC in the tumormicroenvironment (TME) for the
efficacy of immune checkpoint blockade5,6 as well as for so-called
in vivo vaccination approaches, e.g. with oncolytic viruses.7 These
active DC prime, attract and activate tumor-infiltrating T cells, facil-
itating the efficacyof e.g. PD-1blockade.5Unfortunately, under tumor
conditions DC development is often hampered, leading to
a predominance of immature myeloid cells. Indeed, resistance to
immunotherapies such as oncolytic virotherapy, adoptive T cell trans-
fer, or immune checkpoint blockade can in part be explained by
immunosuppressed myeloid subsets present in the tumor
microenvironment.8 This immune suppression is triggered by soluble
factors released in response to chronic inflammation conditions in the
tumormicroenvironment.9,10Monocytes are themainmyeloid subset
recruited to the tumor site,11where they are exposed to tumor-derived
factors that will polarize their differentiation towards immunosup-
pressive subsets like M2-like macrophages, regulatory/tolerogenic
dendritic cells with high production of IL-10, and myeloid-derived
suppressor cells.12,13 These subsets will promote a tolerogenic micro-
environment with high numbers of regulatory T cells that will con-
tribute to tumor growth, survival, angiogenesis and invasion.14
The major reason for disturbed DC development and
functionality in patients with cancer is the production of
high levels of suppressive cytokines. One of the predominant
tumor-associated suppressive cytokines is IL-10.15–18 IL-10
can effectively block DC functionality in all developmental
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stages, during differentiation as well as maturation.19,20 We
have previously shown that addition of IL-10 to fully differ-
entiated CD1a+CD14− monocyte derived DC (MoDC) during
maturation induces re-expression of the monocytic marker
CD14, which is accompanied by a reduced capacity to stimu-
late T cell proliferation and a disturbed cytokine secretion
profile.4,21 Even fully mature DC migrating from skin can
trans-differentiate to CD14+CD163+ M2 macrophage-like
cells with T cell-suppressive features under the influence of
high intradermal levels of IL-10.22,23 These studies indicate
that high IL-10 levels, which are very prevalent in a wide
range of tumor types and different stages of tumor develop-
ment, will interfere with activation of immunocompetent
mature DC with the ability to (cross-)prime and attract anti-
tumor effector T cells.
Here, we carried out exploratory screens on arrays consist-
ing of >1000 functional kinase peptide substrates, to map
pathways involved in DC differentiation and in particular
inhibition by IL-10. We also explored the downstream signal-
ing events of IL-6 as another major cancer-associated cytokine
with powerful DC-suppressive effects.24 Beside the STAT3
and MAPK pathways,25–28 we identified glycogen-synthase
kinase-3β (GSK3β) as a key signaling element vital for proper
DC differentiation, the activity of which was down-regulated
both in IL-10 and IL-6 conditioned DC precursors. Our
functional and in vivo data, with enforced expression of con-
stitutively active GSK3β, demonstrate that therapeutic inter-
ference in tumor-related inhibition of GSK3β activity may
provide a means to render DC and their precursors refractory
to suppression mediated by multiple tumor-derived factors
and that constitutively active GSK3β will facilitate proper
DC development and maturation in situ, and so enhance
T cell dependent tumor control.
Results
PepChip kinomics array analyses of human DC
differentiation and suppression
A kinase peptide substrate array consisting of 1,024 peptides
with specific human phosphorylation sites (PepChip kinome
array, Pepscan Systems, Lelystad, the Netherlands), plotted in
triplicate, was used to comprehensively explore the effects of
the DC-suppressive cytokine IL-10 on the kinome of DC
precursors in a parallel and comparative analysis with a DC
differentiation-inducing cocktail consisting of GM-CSF, IL-4
and TNFα. To avoid donor-dependent variability, we used the
human MUTZ-3 DC cell line model that we previously devel-
oped and described.29,30 MUTZ-3 DC precursors, consisting
of CD34+ and CD14+ cells, were exposed to the cytokines;
based on a 30 versus 90 minute exposure with a activation-
inducing cytokine cocktail, most hits were observed after
90 minutes, which was used as exposure time in all subse-
quent experiments (data not shown). Figure 1(a) shows
a detail of the developed arrays after incubation with lysates
of DC precursors unexposed to cytokines or exposed to
a cocktail of differentiation-inducing cytokines (GM-CSF
+IL-4+ TNF-α) with examples of increased and decreased
phosphorylation of substrates indicated, which resulted from
altered kinase activities in the cytokine-treated cellular lysates.
For all test conditions, a ranked list was made of up- or down-
regulated inferred kinase activities relative to unexposed pre-
cursors. Upon differentiation-inducing cytokine exposure,
rates of more than 2-fold increased or decreased kinase activ-
ities were both around 19%; for IL-10 these rates were 13%
and 23%, respectively (Figure 1(b)). In Tables 1 and 2 the top
15 of peptide substrates with increased or decreased phos-
phorylation levels and their putative upstream kinases are
listed for GM4/TNFα and IL-10, representing 10–15% of all
evaluable substrates.
Most notably, in this exploratory screen GSK3β was iden-
tified as a promising target involved in DC differentiation and
suppression: its activity was increased when applying the
stimulatory GM-CSF/IL-4/TNFα cytokine cocktail (three hits
in the top 15 of ranked kinases with 4.4-, 4.5- and 67-fold
increases in activity, Table 1) and down-modulated when
applying IL-10 (ranked 3rd with a 6.7-fold decrease in activity,
Table 2). Of note, also in IL-6-treated DC precursors, modu-
lated GSK3β activity featured prominently (ranked 1st with
a 50-fold decrease in activity, see Supplementary Table 1).
In view of this clear and opposite modulation of GSK3β
kinase activity between differentiation–inducing and inhibi-
tory cytokines, differential kinase network activities between
GM-CSF/IL-4/TNFα and IL-10 were further visualized
around the GSK3β signalling node by STRING analysis (see
Figure 1(c)). The resulting networks unveiled additional dif-
ferentially modulated kinase activities. Most notably, an upre-
gulated activity of both JAK2 (of which STAT3 is a prominent
substrate) and p38-MAPK in the IL-10 condition became
apparent, which was in line with our previous in vitro obser-
vations in IL-10 and tumor-induced DC suppression and thus
supported the validity of our data set.21,31
To confirm decreased GSK3β activity in IL-10-suppressed
DC, we cultured monocytes from healthy donors for 6 days in
the presence of differentiation-inducing cytokines (GM-CSF
+IL-4), with or without immunosuppressive IL-10 (see
Supplementary Figure 1a). After 6 days of culture, lysates were
generated from the cultures andWestern Blot (WB) analysis was
performed for total GSK3β and pS9GSK3β (the phosphorylated,
inactive form of GSK3β), shown in Figure 1(d). WB analysis
indeed confirmed that there was a shift towards more inactive
GSK3β in the presence of IL-10.
GSK3β inhibition hampers DC differentiation and
functionality
Next, GSK3β was inhibited during MUTZ-3 DC differentia-
tion using a small molecule inhibitor, SB 415286. After
6 days of culture, immature MUTZ3-DC were suppressed
in their development by GSK3β inhibition, demonstrated by
high CD14 levels and absence of the DC-specific markers
CD1a and DC-SIGN (Figure 2(a) and Supplementary
Figure 2).
CD14+ monocytes were similarly differentiated with GM-
CSF and IL-4 (GM4) into CD1a+ immature MoDC in the
presence or absence of the GSK3β inhibitor (Supplementary
Figure 1a). As shown in Figure 2(b), inhibiting GSK3β
severely blocked DC differentiation. This inhibition was
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accompanied by down-regulation of the co-stimulatory mar-
ker CD40 and up-regulation of CD16 and CD141/BDCA3
(Figure 2(c)), all previously identified by us as characteristic
of an M2 macrophage-like phenotype, associated with MoDC
suppression and an impaired capacity for T cell
stimulation.21,23,31 In keeping with this M2-like phenotype,
significantly lower IL-12p70 and higher (but not significantly
so) IL-10 release (Figure 2(d)) and a reduced capacity to
Figure 1. Cytokine exposure alters the kinome of MUTZ-3 DC precursors. (a) Representative details from developed PepChip kinomics arrays loaded with lysates
from MUTZ-3 DC precursors exposed to plain medium (baseline kinase activity) or a DC differentiation-inducing cytokine cocktail consisting of GM-CSF, IL-4 and TNFα
(GM4/TNFα). Each dot represents phosphorylation of a specific peptide substrate; increased or decreased phosphorylation levels upon cytokine exposure are clearly
visible by eye: respective examples are demarcated by surrounding up- or downward oriented arrowheads. (b) Factors of down- or up-regulated phosphorylation
levels of all altered peptide substrates (relative to medium exposed controls) on PepChip arrays loaded with lysates from MUTZ-3 DC precursors exposed to GM4/
TNF-α or IL-10 (numbers of altered substrates out of 1024 total substrates are listed). (c) GSK3β network related kinase activities deduced from Pepchip analyses of
cytokine-exposed MUTZ-3 DC precursors. STRING analysis of the PepChip upstream kinase data was performed to visualize differential kinase network activities. Fold-
change of GM-CSF, IL-4 and TNF-α (GM4/TNF-α) or IL10, both vs. medium control: Red is “up” (fold-change stimulus vs control >1), Green is “down” (fold-change
stimulus vs control <-1); color intensities reflect levels of up- or down-regulation. Double circles indicate p38α (MAPK14), JAK2, and GSK3β signaling nodes. (d)
Western Blot performed on monocytes from two different donors exposed to GM4 or GM4/IL-10 with specific detection of total GSK3β, pS9-GSK3β (inactive GSK3β)
and loading control Histone H3. Proteins and their molecular weights are indicated.
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induce allogeneic T-cell proliferation (Figure 2(e)) were
observed. Of note, IL-10 addition and GSK3β inhibition com-
bined had a synergistic detrimental effect on MoDC differ-
entiation (Figure 2(b)), evident by persistent CD14 expression
and total absence of CD1a expression.
Constitutively active GSK3β renders DC differentiation and
maturation refractory to the suppressive effects of IL-10
As GSK3β inactivation enabled full suppression of MoDC
differentiation by IL-10, we hypothesized that, vice versa,
Figure 2. Inhibition of GSK3β hampers the differentiation of MUTZ-3 precursors and monocytes into DC. (a) Overview of the average percentages of CD14+ or
CD1a+DC-SIGN+ cells in control MUTZ-DC and MUTZ-DC differentiated in the presence of the GSK3β inhibitor SB 415286 (n = 4), mean ±SD are shown. (b) Overview
of the average percentages of CD14+ or CD1a+ cells in control MoDC, MoDC differentiated in the presence of the GSK3β inhibitor, MoDC differentiated with IL-10 or
MoDC differentiated with IL-10 plus GSK3β inhibitor (n = 3), mean ±SEM are shown. (c) FACS histograms for the markers CD40, CD16 and BDCA3 on MoDC
differentiated in the presence or absence of GSK3β inhibitor. The number listed in the graphs are the mean fluorescence intensities. Results are representative of
three different experiments. (d) Secretion of relative IL-12p70 and IL-10 levels by DC treated with or without the GSK3β inhibitor; absolute average IL-12p70 and IL-10
levels in the control MoDC cultures are listed. Shown are mean ± SD from 5 experiments. (e) Overview of the average % of proliferated T cells (CD3+) induced by
MoDC cultured in the absence or presence of the GSK3β inhibitor determined by allogeneic MLR. Day-6 results shown are from 3 experiments (n = 3); ratio peripheral
blood lymphocytes to DC was 10:1. Significance shown as * = P < .05, ** = P < .01 and *** P < .001.
e1631119-6 M. LÓPEZ GONZÁLEZ ET AL.
enforced constitutive GSK3β activation might render DC
refractory to the suppressive effects of IL-10. To investigate
this, CD14+ primary monocytes were transduced with an
adenovirus encoding a constitutively active form of GSK3β
(Ad-CA.GSK3β) or with an adenovirus expressing Luciferase
(Ad-LUC) as a control prior to differentiation induction (as
shown in Supplementary Figure 1a). Monocytes were
checked for transduction after 32h by the expression of the
HA transgene tag (Supplementary Figure 3(a)) and, addi-
tionally, expression of CA.GSK3β was confirmed by western
blot (Figure 3(a)). Indeed, quantitation of WB data (n = 4)
showed that the presence of IL-10 significantly increased the
pS9-GSK3β/total GSK3β expression ratio in the MoDC,
whereas adenovirally enforced expression of CA.GSK3β sig-
nificantly reduced the ratio, even further than levels
observed in non-manipulated MoDC (Figure 3(b)).
Photographs of the cultured MoDC were taken after 6 days
by IncuCyte live imaging, showing the enforced expression
of CA.GSK3β to preserve DC morphology (Figure 3(c)).
MoDC differentiated in the presence of IL-10 presented
a rounded shape and an absence of cluster formation, indi-
cative of poor differentiation32 but when the monocytes were
cultured with IL-10 and Ad-CA.GSK3β, they adopted
a dendritic morphology and formed large clusters, similarly
to the GM4 control (see Figure 3(c)); this cluster formation
was inversely proportional to the pS9-GSK3β/total GSK3β
expression ratio (Figure 3(b)). Consistent with this preserved
DC morphology, Ad-CA.GSK3β transduction resulted in
significantly lower CD14 and increased CD86 levels (Figure
3(d)), and, in addition, reduced the expression of the sup-
pression-related CD16 and CD141/BDCA3 markers21,23,31
and of the IL-10-induced PD-L1 and PD-L2 immune check-
points, see Supplementary Figure 3b. Upon an additional
24h of maturation induction in the presence of CD40L and
INFγ (see Supplementary Figure 1b), even more pronounced
up-regulation of the co-stimulatory marker CD86 was
observed on the IL-10-conditioned DC in the presence of
CA.GSK3β as well as of the maturation marker CD83 (Figure
3(d)). These protective effects against IL-10-induced
immune suppression were not observed for Ad-LUC.
Enforced expression of CA.GSK3β significantly reduced IL-10
release by the IL-10 conditioned and CD40L/IFNγ-stimulated DC
to levels equal to theGM4 control (Figure 3(e)), demonstrating the
involvement of GSK3β in IL-10 expression,33,34 although this was
not accompanied by any significant effect on IL12-p70 secretion
(data not shown). Transduction of theMoDCwithAd-CA.GSK3β
also resulted in a significant reduction in IL-6 release (Figure 3(e)).
To further study the effect of GSK3β on IL-10 exposed
MoDC maturation, iMoDC were transduced with Ad-CA.
GSK3β (see Supplementary Figure 1C). One day after trans-
duction, a maturation-inducing cytokine cocktail consisting
of IL-6, TNFα, IL-1β and PGE2 was added to the DC, with
or without 40ng/mL IL-10. We previously showed that
exposure of DC to IL-10 during their maturation led to
their trans-differentiation into CD14+ macrophage-like cells
with immunoregulatory qualities.22 In transduced cells
(identified by expression of the HA transgene marker)
constitutively active GSK3β blocked the de novo expression
of CD14 (Figure 4(a)). In Figure 4(b) an overview of the
results of 4 different experiments is shown, which clearly
demonstrates the preservation of a typical CD1a+CD14− DC
phenotype by transduction with Ad-CA.GSK3β. Because of
variations in the percentage of cells re-expressing CD14
after maturation in the presence of IL-10, the relative per-
centage of CD14 expressing cells was calculated and shown
to be significantly lower in Ad-CA.GSK3β-transduced DC
(Figure 4(c)).
Constitutively active GSK3β renders MoDC differentiation
refractory to the suppressive effects of melanoma-
derived soluble factors
The protective effect of CA.GSK3β against the suppressive pres-
sure of tumor-derived soluble factors was tested using superna-
tants derived from three melanoma cell lines with known
suppressive effects on MoDC differentiation. As shown in Figure
5(a and b), these supernatants inhibited MoDC differentiation to
varying degrees. Remarkably, the cell lines released varying but
generally low levels of IL-6 (BRO: 3.65 pg/mL, MEL-JUSO 0 pg/
mL, and SK-MEL-28: 0.57 pg/mL) and no IL-10, but adenoviral
expression of CA.GSK3β nevertheless alleviated the observed sup-
pression of differentiation, significantly upregulating CD1a and
CD80 expression (Figure 5(a)) and lowering CD14 as well as
profoundly reducing BDCA3 expression (Figure 5(b)).
Importantly, this also translated into more favourable IL-12p70
and IL-10 release profiles (Figure 5(c)), significantly enhanced
allogeneic CD4+ and CD8+ T cell priming (Figure 5(d)), and
generally increased INF-γ/IL-10 release ratios by primed allo-
geneic T cells (Figure 5(e)). The latter observation thus demon-
strated enhanced type-1 effector T cell functionality in line with
the observed increased IL-12p70:IL-10 ratios (Figure 5(c)).
However, and of note, similarly increased IL-4 release by the
induced allogeneic T cells pointed to balanced activation of effec-
tor T cells rather than a straightforward Th1 polarization
(Supplementary Figure 4).
Constitutively active GSK3β improves tumor immune
surveillance in vivo
Finally we investigated the immune modulatory in-vivo effects
of adenovirally enforced expression of CA.GSK3β in the mel-
anoma TME using the B16.OVA model in C57 BL/6J OlaHsd
mice. Mice were engrafted subcutaneously with 2.5 × 105 cells
of the B16.OVA cell line. Once the tumors reached a diameter
of 3mm the animals were randomized into the different
treatment groups (n = 4 per group). Treatment schedule was
as depicted in Figure 6(a). At day 10 after the first day of
treatment mice were sacrificed to evaluate the TME
composition.
A significant reduction in the fold increase of tumor
volume at day 10 was seen in those mice treated with i.t.
injections of Ad-CA.GSK3β in comparison with the PBS
control group, while no significant differences were observed
between the other groups (Figure 6(b)). Increased expression
of MHC-II was observed on tumor-derived CD11c+B220−,
conventional DC (cDC) in the mice treated with Ad-CA.
GSK3β (Figure 6(c)). Also, a significant increase in the per-
centage of activated cDC (MHC-II+/CD86+) was found, as
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Figure 3. Enforced expression of constitutively active GSK3β renders DC differentiation and maturation refractory to IL-10-mediated suppression. (a) Western Blot
analysis performed on monocytes from two different donors differentiated in the presence of GM4/Ad-LUC, GM4/IL-10/Ad-LUC or GM4/IL-10/AdCA.GSK3β with
specific detection of total GSK3β, pS9-GSK3β (inactive GSK3β) and loading control Histone H3. Protein names and molecular weight are indicated. (b) Averaged
intensity of Western Blot bands, measured with ImageJ, from four independent analyses, for pS9-GSK3β/total GSK3β from monocytes differentiated with GM4/Ad-
LUC, GM4/IL-10/Ad-LUC or GM4/IL-10/AdCA.GSK3β. (c) Images of the corresponding monocyte culture conditions were obtained at day 6 by IncuCyte. (d) Overview
of the average CD14, CD86, and CD83 geometric mean intensity in MoDC differentiated with GM4/Ad-LUC, GM4/IL-10/Ad-LUC or GM4/IL-10/Ad-CA.GSK3β (n = 4),
white bars: unstimulated MoDC, black bars: mDC after CD40L+INFγ stimulation. Mean ±SEM are shown. (e) Average IL-10 and IL-6 (pg/mL) release by MoDC
differentiated with GM4/Ad-LUC, GM4/IL-10/Ad-LUC or GM4/IL-10/Ad-CA.GSK3β (n = 4) after CD40L+ INFγ stimulation. Mean ±SEM are shown, significance shown as
* = P < .05, ** = P < .01 and *** P < .001.
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shown in Figure 6(d). Moreover, significantly increased rates
of the cross-presenting CD8α+ cDC1 subset (of CD11c+/
B220−) and of CD3+CD8+ T cells were similarly observed in
mice treated with Ad-CA.GSK3β (Figure 6(e-f)). A significant
correlation between the frequency of CD8α+ cDC1 with CD8+
T cells (Figure 6(g)) on the one hand, and of CD8+ T cells
with tumor control on the other (Figure 6(h)), confirm
improved immune surveillance upon intratumoral GSK3β
activation.
Discussion
DC are not only essential for the induction of the anti-tumor
T cell response and the generation of long-term immune
memory, but they are also vital for recruitment of effector
T cells to the TME. As such they have been identified as
a major target for tumor immune escape and were shown to
be crucial for the efficacy of immunotherapy involving
immune checkpoint blockade or adoptive cell transfer.5,6
The ability to modulate human DC development and matura-
tion by interfering in signalling pathways would open the way
to enhance the efficacy of immunotherapy in cancer patients
through genetic modification of DC or their progenitors in
the TME or through the use of clinically applicable kinase
inhibitors. In this study, we therefore explored signalling
events downstream of known differentiation-inducing or -
suppressing cytokines. Using a peptide array of over 1000
known human kinase substrates allowed us to take
a functional “snapshot” of the kinome of DC precursors
derived from the human MUTZ-3 cell line and ascertain
how it was modulated by a cocktail of DC differentiation
inducing cytokines (GM-CSF, IL-4, TNFα) or by the cancer-
associated and immune suppressive cytokines IL-10 and IL-6.
Using this unbiased exploratory screening approach, we iden-
tified GSK3β as a pivotal signalling node in the control of DC
differentiation.
GSK3β stood out for its altered activity after cytokine
exposure with three separate hyper-phosphorylated substrates
in the top 15 of the ranked list of peptides with a modulated
phosphorylation state after exposure to the differentiation-
inducing cytokine cocktail. This was a clear indication of its
relevance to DC development. Moreover, the inferred down-
regulation of GSK3β activity after exposure to either IL-10 or
IL-6 further suggested that cytokine-mediated suppression of
DC in general might require a shut-down of GSK3β. We were
able to validate these PepChip findings by inhibition of both
MUTZ-3- and MoDC differentiation by a selective GSK3β
inhibitor, thus mimicking the effects of immune suppressive
cytokines like IL-10 and IL-6.31,35 More importantly, by trans-
ducing monocytes and MoDC with an adenoviral vector
encoding CA.GSK3β, we were able to overcome IL-10
mediated suppression of monocyte-to-DC differentiation
Figure 4. Constitutively active GSK3β renders MoDC resistant to the suppressive effects of IL-10 during maturation. (a) Representative FACS dot plots showing the
expression of CD14 and HA-tagged GSK3β in un-transduced MoDC and adenovirally transduced MoDC (Ad-CA.GSK3β) matured (by a cocktail of IL-6, PGE2, IL-1β, and
TNFα) in the absence or presence of IL-10. Percentages of CD14+ cells are indicated; NB: in the two lower dot plots percentages CD14+ cells of transduced MoDC (i.e.
HA+) are listed. (b) Expression of CD1a (black bars) and CD14 (white bars) on MoDC, matured in the absence or presence of IL-10, the latter also for transduced MoDC
(Ad-CA.GSK3β or Ad-LUC), expressing constitutively active GSK3β. Shown are means ±SD from 4 experiments. (c) Overview of the relative percentages of cells
expressing CD14 in control MoDC (set at 100%) and IL-10 exposed MoDC, un-transduced or transduced by Ad-CA.GSK3β. Shown are means ±SD from 4 experiment.
Significance shown as * = P < .05, ** = P < .01 and *** P < .001.
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and facilitate phenotypic and functional DC maturation upon
stimulation. This finding indicates that inclusion of
a transgene encoding constitutively active GSK3β in viral
vectors targeted to DC or their immediate precursors might
render the in situ transduced DC refractory to the inhibitory
effects of tumor-conditioned suppressive cytokine milieus and
enhance their T cell activation potential. This was further
confirmed in monocyte-to-DC differentiation cultures condi-
tioned by melanoma-derived supernatants, revealing
increased resistance to melanoma-induced suppression of
monocytes that were adenovirally transduced to express CA.
GSK3β. Of note, the inhibitory effects of the employed
Figure 5. Constitutively active GSK3β renders MoDC differentiation refractory to the suppressive effects of melanoma-derived soluble factors. Phenotype, cytokine
release and allogeneic T cell priming capacities are shown of MoDC differentiated in the presence of supernatants derived from the indicated melanoma cell lines
and transduced with Ad-LUC or Ad-CA.GSK3β. (a) Percentages of CD1a and CD80 positive cells and (b) percentages of CD14 and BDCA3 positive cells; Ad-LUC (gray
boxes) or Ad-CA.GSK3β (black boxes). Shown are boxplots with whiskers from 4 different experiments. (c) IL12-p70/IL-10 release ratios; Ad-LUC (gray circles), Ad-CA.
GSK3β (black squares), n = 4. (d) Percentages of proliferated CD4+ and CD8+ allogeneic T cells; Ad-LUC (gray circles) or Ad-CA.GSK3β (black squares). Day-6 results of
an MLR are shown (n = 4); ratio peripheral blood lymphocytes to DC was 10:1. (e) INF-γ/IL-10 release ratios by the T cells from the MLR assay; Ad-LUC (gray
circles), Ad-CA.GSK3β (black squares), n = 4. Significance shown as * = P < .05, ** = P < .01 and *** P < .001.
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Figure 6. Constitutively active GSK3β improves tumor immune surveillance in vivo. Anti-tumor efficacy and phenotypic analysis of the immune infiltrates at
the tumor site 10 days after the different treatments started. (a) 4 mice per group received subcutaneous engraftment of B16.OVA tumor cells that were grown until
a tumor diameter of 3mm was reached. Then 108 viral particles of non-replicating adenoviruses (coding for LUC or CA.GSK3β) or PBS were injected intratumorally
at day 0, 1, 3, 6 and 9. Mice were sacrificed at day 10 and tumors were collected and processed. (b) Shows the fold increase of tumor volume defined as: (length-day
10 * (width-day10)2 * 0.5)/(length-day0 * (width-day0)2 * 0.5)*100 in the different treatment groups. (c) Representative FACS histograms of the MHC-II geometric
mean intensity in the CD11c+B220− conventional DC (cDC) populations in mice from different treatment groups. (d) Scatter plot of the percentage of MHC-II+CD86+
cDC. (e) Scatter plot of the percentages of CD8α+ cross-presenting cDC1s. (f) Scatter plot of the percentages of CD3+CD8+ T cells of total cells. (g) Correlation graph
between the percentages of CD8α+ cDC1 (of cDC) and CD8+ T cells (of T cells) showing the 95% confidence bands of the best-fit line. Pearson r = 0.7705. (h)
Correlation graph between the tumor volume fold increase and the total percentage of CD8+ T cells (of total cells) showing the 95% confidence bands of the best-fit
line. Pearson r = −0.6634. The different treatment groups are shown as PBS (black triangles), Ad-LUC (black squares) and Ad-CA.GSK3β (black circles). 1-way unpaired
ANOVA was applied. Shown are means ±SEM. Significance shown as * = P < .05, and ** = P < .01.
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melanoma cell lines could not be directly related to their
release of either IL-10 or IL-6, with significant inhibition of
DC differentiation observed even in the absence of either
cytokine (as in the case of MEL-JUSO). Importantly, CA.
GSK3β improved DC differentiation in each case, showcasing
its potential efficacy under different suppressive conditions
and its fundamental role in DC differentiation and activation.
The strengths and weaknesses of the employed PepChip
system for functional kinome screens should be recognized.
While the number of included kinase substrates allows for
a comprehensive signalling analysis, the limited robustness of
the system and the promiscuity of most kinases (i.e. one
peptide substrate may be phosphorylated by multiple kinases,
including as yet unidentified ones), limit the PepChip’s power
in terms of definitive pathway analysis. Nevertheless, our data
demonstrate its utility for screening for novel kinase targets in
conjunction with subsequent functional validation. As such it
had previously also proven its worth in the identification of
signalling events accompanying cancer development and
metastasis.36,37
GSK3β is part of a wide range of signal transduction
cascades regulating cellular processes such as glycogen meta-
bolism, differentiation, cytoskeletal organization, cell cycle
regulation, proliferation, and apoptosis. GSK3β can phos-
phorylate several different substrates that each play a role in
different cellular signalling pathways. It is well known that
GSK3β controls the Wnt/β-catenin signalling pathway, which
is involved in cell-cell communication, embryonic develop-
ment, and cancer, and has also been implicated in DC
differentiation.38 Active (i.e. non-phosphorylated) GSK3β
promotes degradation of β-catenin and thereby acts as
a negative regulator of Wnt signalling. The involvement of
the Wnt pathway in regulation of DC development was
indeed suggested by our PepChip kinome analyses revealing
down-regulation by the differentiation-inducing cytokine
cocktail of Casein Kinase 2 (CK2) activity, based on phos-
phorylation of a substrate derived from T-cell Transcription
Factor-4 (Tcf) (ranked 1st with a significant 16.7-fold decrease
in activity, Table 1); Tcf together with Lymphoid enhancer
binding factor (Lef) forms a transcription factor complex
activating transcription of target genes downstream from β-
catenin.39 Furthermore, presenilin, a GSK3β substrate with
a 4.51-fold increased phosphorylation level under influence
of the differentiation-inducing cytokine cocktail (Table 1), has
been reported to interfere with β-catenin signalling.40,41
The direct involvement of GSK3β in inflammation media-
tion has been broadly studied, showing that the inhibition of
GSK3β induces higher expression of IL-10 and lowers the
release of pro-inflammatory cytokines such as IL-12.34,42,43
Our findings also demonstrate that the alteration of the func-
tionality of GSK3β directly affects the cytokines released by
the DC, with significant downregulation of IL-10 production
upon enforced expression of CA.GSK3β. Contrasting observa-
tions regarding the role of GSK3β in DC differentiation have
been published previously.33,44 Of note, these seemingly con-
tradictory observations may be explained by differences in
intracellular and environmental contexts between studies,
resulting in the activation of different signalling cascades
which in turn may be differentially affected by GSK3β kinase
activity. Indeed, most GSK3β substrates require priming/
phosphorylation by other kinases. Differential priming of
GSK3β substrates (e.g. by elements of the MAPK pathways
involved in DC maturation) may lead to opposing effects of
GSK3β activity signalling on DC development and maturation
under inflammatory or suppressed conditions. Nevertheless,
most studies point to a clear role of Wnt signaling in DC
differentiation,38,45–48 wherein the induction of active β-
catenin in DC programs them towards a more tolerogenic
state producing high levels of IL-1049 as well as promoting
regulatory T cell proliferation.46
Both the JAK2/STAT3 and p38-MAPK pathways have
been implicated in disturbed DC differentiation by us and
by others25–28,31,45,50,51 and both were found upregulated
upon IL-10 exposure as demonstrated by our Pepchip analysis
(see Figure 1(c)). We previously showed that combined inhi-
bition of the JAK2/STAT3 and p38-MAPK pathways consis-
tently counteracted inhibition of MoDC differentiation by
a plethora of tumor types.31 We have so far been unable to
specifically link these signalling events to IL-10 or indeed to
any other tumor-associated cytokine. This is most likely due
to the complex, concerted, and possibly synergistic effects of
multiple tumor-derived suppressive factors. Interestingly, we
previously found that siRNA-mediated knockdown of STAT3
also effectively prevented the generation of CD14+ cells dur-
ing IL-10-modulated DC maturation induction.22 As this was
also achieved by transduction of the DCs with constitutively
active GSK3β, this is consistent with cross-talk between these
pathways. Also, p38-MAPK signalling is known to lead to
GSK3β inactivation and activation of the canonical Wnt/β-
catenin signalling pathway.52 Indeed, p38/ERK1/2 signalling
can also induce COX2 activity and so enhance the release of
prostaglandin-E2 (PGE2),53 which in turn can induce GSK3β
phosphorylation and Wnt signalling,50 and suppress DC dif-
ferentiation. Qian et al. further demonstrated that ERK-
mediated inactivation of GSK3 in regulatory DC led to high
levels of β-catenin resulting in the secretion of IL-10.54
Altogether, accumulating data point to different tumor-
associated factors (e.g. IL-10, IL-6, PGE2) exerting their sup-
pressive effects at various stages of myeloid DC development
through converging and communicating signalling elements
encompassing the JAK2/STAT3, p38-MAPK, and GSK3β/
Wnt pathways.
Our in vivo data support the hypothesis that GSK3β acti-
vation in the TME leads to improved tumor control through
activation of DC and their recruitment to the tumor site, and
subsequent increases in infiltrating effector T cells. Our obser-
vation of increased rates of the cDC1 subset is highly relevant
in this regard. cDC1 have previously been identified as CD8α+
and/or CD103+ in both lymphoid and peripheral organs, and
also specifically in B16 tumors.55–59 Spranger et al. showed
that these cross-priming cells were not only crucial for the
priming of tumor-specific T cells but also for recruiting them
to the tumor site, thus facilitating an anti-tumor immune
response and enhancing the efficacy of immune checkpoint
blockade.6 Indeed, in keeping with these previous observa-
tions, we found significant correlations between cDC1 and
CD8+ T cell rates and control of tumor outgrowth; in this
context it is important to note that the numbers of mice
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included in this study and the duration of the experiment
were based on analysis of TME immune composition rather
than tumor control. Immune exclusion in melanoma, result-
ing from low intratumoral cDC1 rates, has been linked to
activation of the Wnt/β-catenin oncogenic signalling
pathway.5 GSK3β is a main regulator of Wnt signalling
through the canonical pathway. Activation of GSK3β will
lead to the degradation of β-catenin, which could in turn
help to overcome immune exclusion and facilitate improved
tumor control. Although our in-vivo observations support this
scenario, more extended in vivo experiments should be per-
formed in order to address long-term benefits from the
treatment.
In conclusion, our data indicate that GSK3β is an attractive
target to counteract tumor-induced suppression of DC devel-
opment and activation. By enforcing constitutive GSK3β
activity at the tumor site, DCs may acquire resistance to
tumor-imposed immune suppression and so help shape
a more immune permissive TME, which in turn may increase
the efficacy of immunotherapy, including oncolytic virother-
apy and immune checkpoint blockade.
Materials and methods
MUTZ-3 culture, lysate preparation and kinase activity
measurements
The human acute myeloid leukemia-derived cell line MUTZ-3
(DSMZ, Braunschweig, Germany), that can be differentiated
to fully functional DC (MUTZ-DC),29,30 was maintained in
culture medium, consisting of MEM-α (Gibco) supplemented
with 20% Fetal Calf Serum (FCS; HyClone), 100 IU/ml
sodium penicillin (Yamanouchi Pharma), 100 µg/ml strepto-
mycin sulfate (Radiumfarma-Fisiopharma), 2 mM
L-glutamine (Invitrogen Life Technologies), 0.01 mM
2-Mercapto-Ethanol (2-ME, Merck), and 10% conditioned
medium from the human renal cell carcinoma cell line 5637,
as described.29,30 Prior to kinase profiling, MUTZ-3 cells were
washed and placed in low serum (1% FCS) culture medium
before overnight culture at a density of 1 million/ml (to a total
of 5 million cells per condition) in 6-well tissue culture plates
(Greiner). Subsequently, cytokines were added for 90 minutes
to study the effects of cytokine-dependent differentiation
induction or inhibition of kinase activity in the DC precur-
sors. Either a differentiation-inducing cocktail consisting of
100 ng/mL GM-CSF (Berlex), 2.5 ng/mL TNFα (R&D
Systems) and 20 ng/mL IL-4 (R&D Systems) was added, or
IL-10 (eBiosciences) or IL-6 (R&D Systems), both at 50 ng/ml,
which are concentrations at which DC differentiation is com-
pletely blocked.30,31 Cells not exposed to cytokines served as
negative control for baseline activity. After 90 minutes of
incubation, cells were harvested and washed twice with ice-
cold PBS and processed further essentially as described.36,60
The PepChip kinomics Array (Pepscan, Lelystad, The
Netherlands) consisting of 1024 peptides representing specific
human Tyrosine, Threonine and Serine phosphorylation sites
was used to comprehensively evaluate the effects of the dif-
ferent cytokines on the kinome of the MUTZ-DC progenitors.
In short, the cells were harvested in 200μl lysis buffer
(Mammalian Protein Extraction Reagent) containing HALT
protease inhibitor cocktail (1:100) and HALT phosphatase
inhibitor cocktail (1:100) (both from Thermo Scientific). The
cell lysates were diluted (1:2) in dilution buffer (50 mM
HEPES-KOH, pH 7.5, 10 mM MgCl2, 10 mM MnCl2), cen-
trifuged, and 10 µl of the activation mix (50% glycerol, 5mM
DTT, 50 mM MgCl2, 50 mM MnCl2, 250 µg/ml PEG8000,
250 µg/ml BSA) with 20 μCi33P-ATP (Amersham Biosciences)
was added to 70 µl lysate. The mixture was centrifuged at
14000 rpm for 5 min at RT, and loaded onto the PepChips.
The slides were incubated at 37°C for 2 hours in a closed
humid box to allow for phosphorylation to take effect. The
PepChips were then washed 3 times for 10 min with PBS, 1%
SDS, 1mM DTT, followed by 3 times Milli-Q water (Merck).
Subsequently, the slides were dried and exposed to
a phosphor-imager screen (GE Healthcare) for 72h.
Pepchip data acquisition and statistical analyses
Data acquisition and analysis was performed as described
previously.36,37 In short, the acquisition of the peptide array
was performed using a phosphor-imager (StormTM, GE
Healthcare). Each PepChip kinomics array contained 1024
human peptide sequences spotted in triplicate.
Phosphorylation per substrate spot was quantified on
a phosphor-imager and corrected for individual background
levels using a digital grid and algorithms provided by the
manufacturer. Data were normalized between replicates on
a chip and between chips by intensities of control substrate
spots included in the arrays. An exploratory screen with one
set of arrays was performed, followed by a second, independent
set, which was included for statistical significance testing. Spot
densities, corrected for individual background distributions,
were analysed using grid tools provided by the manufacturer.
Exposed phosphor-imager screens were scanned and the
obtained images from the phosphor-imager (in .GEL format,
i.e. with square rooted intensity figures [Fluorescence Imaging –
principles and methods, Amersham Biosciences handbook
2002–10, p.134]) with linearized intensities were quantified by
ScanAlyse Software (http://graphics.stanford.edu/software/sca
nalyze/). Data were imported to Microsoft Excel for further
analysis. Inconsistent data sets (i.e., SD between the different
data points exceeding 1.96 of the mean value) were excluded
from further analysis. Spots were averaged and included for
dissimilarity measurement to identify induced or reduced
kinase activities in the cytokine-exposed DC precursors relative
to unexposed precursors. A list of peptides was generated by
ranking the spots, resulting in an “up” or “down” assignation for
each peptide’s phosphorylation status, which in turn was used
to explore cytokine-induced changes in signalling networks.36,37
Statistical significance levels indicated in Table 1–2 (and
Supplementary Table 1) were based on a t-test performed with
data from two independent PepChip analyses encompassing
2 × 3 data points.
Pepchip data visualization
Upstream kinases for substrate peptides from PepChip (based
on literature and provided by the manufacturer, www.pepscan.
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com; available on request) were mapped from HPRD (Human
Protein Reference Database, http://www.hprd.org/) to SwissProt
accessions using Biomart (http//www.biomart.org). In case mul-
tiple substrate peptides mapped to the same upstream kinases,
the median fold change of IL-4/GM-CSF/TNFα vs control and
IL-10 or IL-6 vs control were used. Upstream kinases identified
in the IL-4/GM-CSF/TNFα condition and the IL-10 condition
were combined and a non-redundant kinase list was imported in
STRING (http//string-db.org) to derive the protein-protein con-
nectivity table. The connectivity table was loaded in Cytoscape
version 2.7 (http//www.cytoscape.org) to visualize protein-
protein interactions constructed around GSK3β; nodes were
intensity-colored by fold change (attribute table) for the IL-4/
GM-CSF/TNFα condition and the IL-10 condition, respectively.
Melanoma cell lines, MUTZ-3 and monocyte-derived DC
culture
MUTZ-3 cells were differentiated to DC as described
previously.61 In short, cells were differentiated for 6 days in
the presence of GM-CSF (100 ng/mL), TNFα (2.5 ng/mL) and
IL-4 (20 ng/mL), in the presence or absence of 10 μM SB
415286 (Merck) a selective inhibitor of GSK3β. Cytokines and
GSK3β inhibitor were refreshed on day 3. After 6 days the
differentiated DC were harvested and the phenotype of the
DC was determined by flow cytometric analysis.
The human melanoma cell lines MEL-JUSO, BRO, and SK-
MEL-2862 were a kind gift from Dr. Erik Hooijberg, Dr. Saskia
Cillessen and Dr. Sue Gibbs, respectively (all Amsterdam UMC,
Vrije Universiteit). Their identities were confirmed by short tan-
dem repeat (STR) analysis, using the human cell line authentica-
tion service provided by Eurofins based on 21
independent PCR-single-locus-technology, following the ISO
17025 standard guidelines (https://www.eurofinsgenomics.eu/en/
genotyping-gene-expression/applied-genomics-services/cell-line-
authentication/) . All melanoma cell lines were cultured in Iscove’s
Modified Dulbecco’sMedium (IMDM) (BioWhittaker® by Lonza)
with 10% heat inactivated (h.i.) fetal calf serum (FCS) (HyClone),
100 IU/mL sodium-penicillin, 100 μg/mL streptomycin, 2 mM
L-glutamine and 50 μM β-mercaptoethanol added. Supernatants
(SN) from the cell lines were collected from confluent monolayer
cultures after 24h at 37°C and 5% CO2.
For the in vivo experiments, the murine melanoma cell line
B16.OVA was used, kindly provided by Professor Richard
Vile (Mayo Clinic, Rochester, MN, USA). This cell line was
cultured in RPMI 1640 supplemented with penicillin (100U/
mL), streptomycin (100 μg/mL), L-Glutamine (2mM), 10% of
FBS and G-418 (5mg/mL).
MoDC were generated as described previously.31 Peripheral
blood mononuclear cells (PBMC) were isolated from healthy
human volunteers by density centrifugation over Lymphoprep
(Nycomed AS, Oslo, Norway). CD14+ monocytes were isolated
from PBMC by CD14+ MACS (Miltenyi Biotec). After washing,
the cells were collected for (>95%) purity check by flow cyto-
metric analysis or differentiated for 6 days in RPMI 1640 with
HEPES and L-Glutamine (Lonza BioWhittaker) supplemented
with 10% fetal bovine serum (FBS; HyClone), 100 IU/ml sodium
penicillin (Yamanouchi Pharma), 100 µg/ml streptomycin sul-
fate (Radiumfarma-Fisiopharma), 2 mM L-glutamine
(Invitrogen Life Technologies), and 0.01 mM 2-ME (Merck),
100 ng/ml GM-CSF (Immunotech) and 20 ng/ml IL-4
(Strathmann Biotec, Hamburg, Germany). Monocytes were pla-
ted in a T75 flask at 4 million per flask or in a 48 well plate at
a 0.12 million per well. To inhibit GSK3β signaling during DC
differentiation, 10 μMSB 415286 was administered to themono-
cytes, 30 minutes prior to administration of GM-CSF and IL-4
(GM4) (see Supplementary Figure 1a). After 6 days of differen-
tiation, DC were harvested and analyzed by flow cytometric
analysis or cultured together with allogeneic lymphocytes in
a mixed leukocyte reaction (MLR), see Supplementary Figure 1a.
To determine the effect of GSK3β activation on IL-10 and
melanoma SN modulated DC differentiation, monocytes were
cultured with GM-CSF (100ng/ml), IL-4 (20ng/ml), IL-10
(10 ng/ml) or exposed to 30% of melanoma-derived SN. Thirty
minutes prior to administration of the cytokines or supernatants,
the monocytes were transduced with an adenovirus serotype 5
containing the cDNA encoding a constitutively active form of
GSK3β (Ad-CA.GSK3β; a kind gift of Dr Hyo-Soo Kim and co-
workers, Seoul, Korea),63 at a multiplicity of infection (MOI) of
500 pfu. An Adenovirus encoding Luciferase (Ad-LUC) was
used to control for the effect of virus infection at the same
MOI of 500 following the same procedure. After 6 days of
differentiation, DC were either harvested and used for flow
cytometric or MLR analysis or exposed to irradiated CD40L-
expressing J558 cells in a 1:1 ratio together with 1000 IU/mL of
recombinant human interferon gamma (rh(IFN)-γ)
(e-Bioscience) in GM-CSF and IL-4 containing MoDC culture
medium (see Supplementary Figure 1b); after 24h, the SN were
collected and analyzed by Cytometric BeadArray (CBA) analysis
using the Inflammation kit of BD Biosciences) and cells were
harvested and phenotypically evaluated by flow cytometric
analysis.
To determine the effects of GSK3β activation during IL-10
exposed maturation of MoDC, 6-day cultured and differen-
tiated immature MoDC (iMoDC) were transduced with Ad-
CA.GSK3β or Ad-LUC, at MOI 500 pfu. 24h after transduc-
tion, a maturation-inducing cytokine cocktail consisting of
50 ng/ml TNFα (R&D Systems), 100 ng/ml IL-6 (R&D
Systems), 25 ng/ml IL-1β (R&D Systems) and 1 μg/ml PGE2
(Sigma-Aldrich) was added (with or without 40ng/mL of IL-
10) (See Supplementary Figure 1c). After 48h, cells were har-
vested and evaluated for phenotypic maturation by flow cyto-
metric analysis.
Incucyte live imaging
Monocytes were obtained and cultured into MoDC as pre-
viously described. Monocytes under GM4+ Ad-LUC, GM4
+ IL-10+ Ad-LUC, and GM4+ IL-10+ Ad-CA.GSK3β were
incubated for 6 days at 37°C and 5% CO2 in the IncuCyte®
(Essen Bioscience), and pictures were taken of the culture
wells every 4 hours. The images were analyzed with
IncuCyte ZOOM software (Essen Bioscience).
Western blot
Cell lysates were generated using 1x RIPA buffer
(ThermoFisher) in combination with protease and phosphatase
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inhibitor (ThermoFisher) and protein concentration was deter-
mined using the BCA Protein Assay Kit following the manufac-
turer’s instructions (ThermoFisher). Denatured lysates were
loaded onto a pre-cast 4–20% protein gel (BioRad) and blotted
using standard methods.31 For protein detection, the blots were
incubated overnight with primary antibodies against total
GSK3β and pS9GSK3β both at 1:1000 (Cell Signaling
Technology) and an antibody against Histone H3 was used as
a loading control at 1:1000 (Cell Signaling Technology).
Hereafter, blots were incubated for 1h with a secondary 680RD
labeled antibody (Goat anti-Rabbit) in a 1:10000 dilution (LI-
COR). Fluorescence detection was used to visualize the protein
bands by Licor Odyssey machine. Quantification of the bands
was determined by the use of ImageJ software.
In vivo study
4–6 week old C57 BL/6JOlaHsd mice were commercially
obtained (Envigo, Indianapolis, IN, USA). After one week of
quarantaine, mice were kept in a Biosafety level 2 facility and
were subcutaneously engrafted in the left flank with 2.5 × 105
of the B16.OVA cells in 100 µl of RPMI 1640 (not supple-
mented). When the tumors reached a volume of 3mm (after
10 days), animals were randomly assigned to the different
treatment groups (n = 4 per group) and treatment com-
menced (at day 0); for treatment schedule see Figure 6(a).
Mice were injected intratumorally with 50µl of PBS, Ad-LUC
or Ad-CA.GSK3β, containing 108 viral particles (vp), using
30G insulin needles. Mice received the same treatment at day
0, 1, 3, 6 and 9. Tumors were measured every day after start of
treatment with the use of an electronic calliper. Tumor
volume was calculated as length * (width)2 * 0.5. Tumor
volume fold increase was defined as (tumor volume at day
10)/(tumor volume at day 0)*100. Mice were observed daily
and euthanized at a pre-determined time point (day 10) to
compare the immune status of the different treatment groups.
NB: one mouse in the Ad-LUC control group was lost to TME
composition analysis due to an open wound on the tumor.
Biological samples were then collected and processed (i.e.
passed through 70 mm cell strainers in order to obtain
a single-cell suspension) for analysis by Flow Cytometry.
Flow cytometry
APC-, PE-, PerCPCy5.5-, FITC-, BV711-, PECy7-, BV421,
BV650- and AF700- labeled antibodies directed against human
CD14, CD34, CD1a, CD40, CD16, CD4, CD8 (BD Biosciences),
CD83 (Coulter Immunotech, Marseilles, France), CD209/DC-
specific ICAM-grabbing nonintegrin (DC-SIGN; BD
Pharmingen), CD141/BDCA3 (Miltenyi Biotec), CD80, CD86,
CD1a, CD14, CD83 (BD Pharmingen), PD-L1 (eBioscience),
CD40, PD-L2, CD3 (BD Horizon) and CD45, HLA-ABC
(Biolegend) were used for flow cytometric analyses. Antibody
staining was performed in PBS supplemented with 0.1% BSA
and 0.02% sodium-azide for 30 min at 4°C. To determine DC
transduction efficiency of Ad.CA.GSK3β (which also encodes
the hemagglutinin (HA) marker gene), DC were harvested and
permeabilized using the BD Fix-Perm kit, following manufac-
turer’s guidelines. After fixation and permeabilization, a FITC-
labeled anti-HA antibody was added (Miltenyi Biotec). After
30 minutes incubation, cells were washed and analyzed.
Analyses were performed on a FACSCalibur or Fortessa flow
cytometer using Cellquest-Pro analysis software (BD
Biosciences) or Kaluza flow cytometry analysis software
(Beckman Coulter).
For the in vivo data, FITC-, PE-, PE-CF594-, PE-Cy5-,
PerCP-Cy5.5- and PE-Cy7- labeled antibodies directed against
mouse CD11c, CD86, CD8α, CD3 (BD Horizon), B220, MHC-
II, CD45 (Biolegend), and CD8β (eBioscience) were used for
flow cytometric analyses. Staining was performed as described
above. Measurements were done with the Sony SH800Z cyt-
ometer (Sony, Tokyo, Japan) and data further analyzed with
Kaluza flow cytometry analysis software (Beckman Coulter).
Mixed leukocyte reaction (MLR)
An MLR was performed with 6 day-differentiated immature
MoDC (iMoDC) that were added as stimulator cells to round-
bottom, 96-well, tissue-culture plates at 104/well. As respon-
der cells, 105 peripheral blood lymphocytes (PBL) labeled with
3μM 5(6)-Carboxyfluorescein (CFSE, Sigma Aldrich) per well
were used, which were obtained from PBMC after CD14+
monocyte depletion by MACS (Miltenyi Biotec). Stimulation
of PBL was performed in duplicate. Unstimulated PBL were
used as negative controls. Cells were cultured in IMDM
(Lonza) supplemented with 10% pooled human serum
(Sanquin Blood Supply, Amsterdam, The Netherlands), 100
IU/ml penicillin and 100 μg/ml streptomycin. At day 6, super-
natants were collected and samples were taken from each well
and T cell proliferation (by CFSE dilution) was determined by
flow cytometric analysis.
Cytokine measurement
MoDC, cultured in the presence or absence of the GSK3β
inhibitor SB 415286 (10 μM), or transduced by Ad-CA.GSK3β
or Ad-LUC, both at a MOI of 500, were stimulated for
24 hours with interferon (IFN)-γ (e-Bioscience) and irra-
diated J558 cells transfected with CD40L as described
previously6. The levels of IL−12p70, IL−10, IL−6, IL−8,
TNFα and IL−1β produced by the immature or mature DCs
were determined by Cytometric Bead Array (CBA) analysis
(BD Biosciences, San Diego CA) according to the manufac-
turer’s protocol (BD, 551811).
Additionally, the expression of INF-γ, IL-10 and IL-4 pro-
duced by the T cells, cultured as described in “Mixed lympho-
cyte reaction” paragraph, was determined using Cytometric
Bead Array (CBA) analysis (BD Biosciences, San Diego CA)
according to the manufacture’s protocol (BD, 560484).
Statistical analyses
Differences between test conditions were analyzed by paired
2-sided Student’s T-test, 1-way unpaired ANOVA using
Fisher LSD test, or 2-way ANOVA matched multiple compar-
isons using Sidak corrections, in the case of the PepChip data
in conjunction with False Discovery Rate analysis, using
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Microsoft Excel or Prism GraphPad v5.0 software. Differences
were considered significant when p < .05.
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